FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Update

FibroBiologics, Inc. (NASDAQ:FBLG) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,500,000 shares, an increase of 33.9% from the August 15th total of 1,120,000 shares. Currently, 5.6% of the company’s shares are short sold. Based on an average trading volume of 418,700 shares, the days-to-cover ratio is currently 3.6 days.

Analyst Ratings Changes

Separately, EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th.

FibroBiologics Stock Performance

FBLG traded down $0.01 during trading on Monday, reaching $3.25. The company had a trading volume of 819,030 shares, compared to its average volume of 259,040. FibroBiologics has a 12 month low of $1.08 and a 12 month high of $55.00. The business’s fifty day moving average price is $3.26 and its 200 day moving average price is $7.37.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). On average, analysts forecast that FibroBiologics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of FBLG. Fund Evaluation Group LLC acquired a new position in shares of FibroBiologics during the 2nd quarter worth approximately $5,265,000. Cascade Financial Partners LLC bought a new stake in FibroBiologics in the 2nd quarter valued at $1,572,000. Transform Wealth LLC bought a new stake in FibroBiologics in the 2nd quarter valued at $668,000. Bank of New York Mellon Corp acquired a new position in FibroBiologics in the 2nd quarter valued at $342,000. Finally, RMR Wealth Builders bought a new position in FibroBiologics during the 2nd quarter worth $186,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.